GLP-1 gets the headlines, but tirzepatide's second target — the GIP receptor — is central to its design.
GIP is secreted by K-cells in the upper small intestine in response to nutrients. Like GLP-1, it stimulates glucose-dependent insulin secretion. For years GIP was considered a less promising drug target than GLP-1, partly because its insulinotropic effect appears blunted in type 2 diabetes. Tirzepatide's success has renewed scientific interest in what GIP-receptor activation contributes.
Beyond insulin secretion, GIP receptors are expressed in adipose tissue, bone and regions of the brain. Hypothesized contributions of GIP agonism include effects on lipid buffering and fat metabolism, central pathways affecting food intake, and possibly improved tolerance of GLP-1-related nausea. These are areas of ongoing study; the literature does not yet fully resolve how much each effect matters in people.
The clinical rationale is empirical: when both receptors are engaged, outcomes in trials exceeded GLP-1 agonism alone. In SURPASS-2, tirzepatide produced larger A1c and weight reductions than semaglutide 1 mg in type 2 diabetes. Whether this reflects true receptor synergy, differences in achievable dosing, or both is still debated among researchers.
Tirzepatide opened a wave of multi-receptor incretin drugs in development, including triple agonists that add glucagon-receptor activity. The field is moving quickly. For patients, the practical takeaway is that “GLP-1” is now an umbrella term — different medications target different combinations of receptors, which affects their efficacy and side-effect profiles.
This explains the science behind tirzepatide's design; it is not a recommendation. Suitability, dosing and safety are individual medical decisions. Compounded tirzepatide is not FDA-approved.
One of the most interesting puzzles in the field is that both GIP-receptor agonists and GIP-receptor antagonists have shown weight benefits in some experimental settings. Several explanations have been proposed: that sustained agonism functionally desensitizes the receptor (behaving somewhat like antagonism over time), that GIP acts at different sites with opposing effects, or that the GIP contribution mainly amplifies GLP-1 signaling rather than acting independently. Tirzepatide is an agonist at both receptors, and its success has made resolving this debate a priority because it shapes how the next wave of drugs is designed. Researchers are also studying GIP's effects outside metabolism — in bone, the cardiovascular system and the brain's reward circuitry. None of this changes what the trials showed, but it explains why scientists describe tirzepatide's mechanism as well-evidenced in outcome yet incompletely understood in detail. Expect this picture to keep evolving as more multi-receptor drugs are tested.
Citations are provided for educational reference. This article summarizes published research in plain language and is not medical advice. Always consult a licensed clinician.
No. Both are incretin hormones released after eating, but they act on different receptors. Tirzepatide activates both; semaglutide activates only the GLP-1 receptor.
In head-to-head trials tirzepatide outperformed a GLP-1-only comparator on glucose and weight, but how much of that is due to GIP specifically is still being studied.
GIP-receptor pharmacology is an active research area, but the approved products combine GIP with GLP-1 (and, in development, glucagon) activity.